webinar register page

Webinar banner
Breakthrough or Breakdown: Should the FDA Have Approved the New Alzheimer’s Drug? Should Patients Take It?


Jul 12, 2021 09:41 AM

Webinar logo
* Required information


Aaron S. Kesselheim
Physician & Professor @Harvard Medical School & Brigham and Women’s Hospital
Aaron S. Kesselheim, MD, JD, MPH is a professor of medicine at Harvard Medical School and in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital in Boston. A world-renowned expert in ethics & health policy related to drug development, Dr. Kesselheim was one of the three members of the FDA Advisory Committee who resigned over the decision.
Jason Karlawish
Physician & Professor @University of Pennsylvania & Penn Memory Center
Jason Karlawish, MD, a Hastings Fellow, is professor of medicine, medical ethics & health policy and neurology at the University of Pennsylvania’s Perelman School of Medicine and co-director of the Penn Memory Center. Dr. Karlawish’s recent book is entitled, “The Problem of Alzheimer's: How Science, Culture, and Politics Turned a Rare Disease into a Crisis and What We Can Do About It.”